Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Scientists Examine HIV's Effect On Immune System
A study by researchers from Duke University and the University of North Carolina-Chapel Hill and published in PLoS Medicine has found that upon infection "three lines of attack by the immune system are quickly neutralized by HIV," findings they hope "will provide a better understanding of how to develop a vaccine to protect against the virus," the Raleigh News & Observer reports. The study, lead by Duke"s Barton Haynes, showed that HIV, "once considered a slow if stealthy invader, actually works incredibly fast at disarming key immune fighters in the body." Haynes said scientists still have a difficult task in developing a vaccine, adding, "It would have to be different than any other vaccine made" (Avery, 7/7).
generic viagra online
Competitiveness And Perfectionism: Common Traits Of Both Athletic Performance And Disordered Eating
Timberline Knolls, one of the country"s leaders in the treatment of eating disorders, is recognizing well-known tennis star, Monica Seles, for disclosing her history with an eating disorder in her new book Get a Grip. Ms. Seles" display of courage and candor has the potential to help many others who have similar struggles, especially young female athletes.
News of the day
Secretary Sebelius Announces Availability Of $40 Million In Grants To Help Insure More Children
HHS Secretary Kathleen Sebelius announced the availability of up to $40 million in grants to help reach families whose children qualify but are not yet enrolled in state Medicaid and Children"s Health Insurance Programs (CHIP). Sebelius was joined for the announcement by Colorado Governor Bill Ritter. Colorado has been a leader in the effort to provide health insurance coverage to more children.
Nutrition

NanoViricides, Inc. Eye Drug Testing Has Begun

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that testing of its topical eye drops drug candidate has begun at two different, independent facilities. Testing of this broad-spectrum, topical, eye drug candidate by a major pharmaceutical company ("Party") is now in progress. The Company had previously announced in March that it had signed a Material Transfer Agreement with this Party. In addition, the Company is also evaluating this drug candidate against herpes keratitis of the eye at Thevac, LLC, a spin-off of the Louisiana State University (Study Director, K. G. Kousoulas, PhD). The testing at the two facilities will independently evaluate performance of this drug candidate against several types and strains of many different viruses that cause keratitis or conjunctivitis of the eye. Cell culture studies as well as animal studies with different animal models have been planned. "Execution of the material transfer agreement (MTA) is a step towards a potential licensing agreement," said Eugene Seymour, MD, MPH, CEO of Nanoviricides, Inc. The terms of the agreement do not allow the disclosure of the identity of the Party or the exact terms of the MTA. HSV and some adenoviruses cause most of the cases of keratitis, a serious infection of the cornea. Importantly, HSV infection can lead to corneal scarring that may necessitate corneal transplantation. In addition, some adenoviruses cause a majority of conjunctivitis cases ("pink eye"). The remaining cases of conjunctivitis, caused by bacteria, are treatable with topical antibiotics. Currently, there are no effective treatments for viral diseases of the exterior portion of the eye. The Company has already demonstrated strong efficacy against an adenovirus-caused external eye disease called epidemic kerato-conjunctivitis (EKC). Rapid clinical improvement in the treated animals was reported by independent researchers who tested the effects of the nanoviricides drug candidate against adenoviral EKC. Based on computer modeling, the Company believes that the broad-spectrum nature of the ligand used in this nanoviricide should enable it to be effective against HSV. The total market for all forms of viral conjunctivitis/keratitis is estimated to be in the billions of dollars. The incidence of severe herpes (HSV) keratitis is estimated to be 250,000 cases per year in the USA. In Japan, where EKC is a reportable disease, it is estimated that there are at least one million cases per year. The number of cases of non-specific conjunctivitis (pink eye) is considered to be far greater, possibly into tens of millions in the US, and into hundreds of millions worldwide. NanoViricides


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009